CPT code 44369 represents an endoscopic therapeutic procedure in which the provider examines the upper small intestine (excluding the ileum) and destroys tumors, polyps, or other lesions using laser or radiofrequency energy. This code captures a targeted, energy-based ablation approach distinct from other forms of lesion destruction and is relevant for practices offering advanced endoscopic therapies. Nationally, this code matters for facility and professional billing, appropriate coding of endoscopic ablation services, and payer coverage decisions for minimally invasive treatment of benign, precancerous, or obstructing small-bowel lesions.

Key payers in standard coverage analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find concise benchmarks on expected use and site-of-service patterns, clinical context about the procedure and indications, and notes on coding specificity that affect claim adjudication and billing practice. The publication outlines where the procedure is typically performed (hospital outpatient departments and ambulatory surgical centers), clarifies the service type as an endoscopic therapeutic ablation, and identifies common operational considerations relevant to billing and documentation. Data not available in the input for payer-specific reimbursement rates, associated taxonomies, and ICD-10 diagnoses are noted as such.